OliX Pharmaceuticals, Inc (KOSDAQ:226950)

South Korea · Delayed Price · Currency is KRW

114,800

-21,800 (-15.96%)

Jul 20, 2026, 3:30 PM KST

196.26% (1Y)

Market Cap	2.41T +214.1%
Revenue (ttm)	17.26B +193.3%
Net Income	-12.25B
EPS	-596.21
Shares Out	20.99M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	295,152
Open	132,600
Previous Close	136,600
Day's Range	114,000 - 132,600
52-Week Range	36,350 - 217,000
Beta	0.36
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About OliX Pharmaceuticals

OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company’s products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepatitis; and OLX301D for subretinal fibrosis. The company has a license and collaboration agreement with Hansoh Pharmaceuticals; development collaboration ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2010

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 226950

Full Company Profile

Financial Performance

In 2025, OliX Pharmaceuticals's revenue was 14.67 billion, an increase of 158.35% compared to the previous year's 5.68 billion. Losses were -15.74 billion, -61.28% less than in 2024.

Financial Statements